These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23380621)

  • 1. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.
    Seguin J; Brullé L; Boyer R; Lu YM; Ramos Romano M; Touil YS; Scherman D; Bessodes M; Mignet N; Chabot GG
    Int J Pharm; 2013 Feb; 444(1-2):146-54. PubMed ID: 23380621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a liposomal formulation of the natural flavonoid fisetin.
    Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG
    Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice.
    Ragelle H; Crauste-Manciet S; Seguin J; Brossard D; Scherman D; Arnaud P; Chabot GG
    Int J Pharm; 2012 May; 427(2):452-9. PubMed ID: 22387278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice.
    Touil YS; Seguin J; Scherman D; Chabot GG
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):445-55. PubMed ID: 21069336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study.
    Bothiraja C; Yojana BD; Pawar AP; Shaikh KS; Thorat UH
    Expert Opin Drug Deliv; 2014 Jan; 11(1):17-29. PubMed ID: 24294925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite.
    Touil YS; Auzeil N; Boulinguez F; Saighi H; Regazzetti A; Scherman D; Chabot GG
    Biochem Pharmacol; 2011 Dec; 82(11):1731-9. PubMed ID: 21840301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
    Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
    Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-encapsulation of fisetin and cisplatin into liposomes: Stability considerations and in vivo efficacy on lung cancer animal model.
    Renault-Mahieux M; Seguin J; Vieillard V; Le DT; Espeau P; Lai-Kuen R; Richard C; Mignet N; Paul M; Andrieux K
    Int J Pharm; 2024 Feb; 651():123744. PubMed ID: 38145778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
    Huang FY; Mei WL; Li YN; Tan GH; Dai HF; Guo JL; Wang H; Huang YH; Zhao HG; Zhou SL; Li L; Lin YY
    Eur J Cancer; 2012 Sep; 48(14):2260-9. PubMed ID: 22257793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
    Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
    Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
    Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
    J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation.
    Renault-Mahieux M; Vieillard V; Seguin J; Espeau P; Le DT; Lai-Kuen R; Mignet N; Paul M; Andrieux K
    Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34206986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total flavonoids of Daphne genkwa root significantly inhibit the growth and metastasis of Lewis lung carcinoma in C57BL6 mice.
    Zheng W; Gao X; Chen C; Tan R
    Int Immunopharmacol; 2007 Feb; 7(2):117-27. PubMed ID: 17178377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and photobiological study of a novel chlorin photosensitizer BCPD-18MA for photodynamic therapy.
    Zhang J; Deng L; Yao J; Gu P; Yang F; Wang X; Liu W; Zhang Y; Ke X; Jing X; Chen J
    Bioorg Med Chem; 2011 Sep; 19(18):5520-8. PubMed ID: 21855352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
    J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy.
    Li C; Cui J; Wang C; Li Y; Zhang H; Wang J; Li Y; Zhang L; Zhang L; Guo W; Wang Y
    Eur J Pharm Biopharm; 2008 Oct; 70(2):657-65. PubMed ID: 18582570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.